Last updated: February 20, 2026
What is NDC 00131-2478?
NDC 00131-2478 is the National Drug Code for Liraglutide (Victoza), a glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes management and weight control. Manufactured primarily by Novo Nordisk, Victoza also has an approved indication for chronic weight management under Saxenda.
Market Landscape
Therapeutic Area
Type 2 Diabetes and Obesity
The GLP-1 receptor agonist market is expanding due to increased diabetes prevalence and obesity rates globally.
Key Competitors
- Semaglutide (Ozempic, Wegovy) by Novo Nordisk
- Dulaglutide (Trulicity) by Eli Lilly
- Exenatide (Bydureon, Byetta) by AstraZeneca
Market Size
- The global diabetes drugs market was valued at approximately $52 billion in 2022, projected to reach $65 billion by 2027 (CAGR: 4.7%) [1].
- GLP-1 receptor agonists accounted for roughly 35% of this segment, with sales of $18 billion in 2022.
Adoption Trends
- Increasing use for both glycemic control and weight management.
- Growing preference for once-weekly formulations (e.g., semaglutide) over daily injections.
- Rising off-label use for obesity treatment expands market potential.
Market Penetration of Victoza/NDC 00131-2478
- Estimated to hold a market share of 15%-20% within GLP-1 class, with significant revenue contributions from established base therapy.
Regulatory and Reimbursement Landscape
- Widely reimbursed in developed markets like the US, EU, and Japan.
- Price negotiations and formulary placements influence market share.
Price Analysis
Current Pricing Environment
- Wholesale Acquisition Cost (WAC): Victoza's WAC per 1.8 mL pen (6 mg dose) is approximately $700–$750.
- Average Selling Price (ASP): Estimated at around $680–$720 based on recent claims data.
- Patient out-of-pocket costs: Typically $30–$50/month with insurance, higher without coverage.
Pricing Trends
- Slight price reductions in response to biosimilar and generic entry projections.
- Price competition with semaglutide's once-weekly options lowers the retail cost.
Pharmacoeconomic Factors
- Cost-effectiveness assessments favor GLP-1s like Victoza when considering reduction in cardiovascular risks, weight, and glycemic control.
Price Projection (Next 3-5 Years)
| Year |
Estimated Wholesale Price |
Rationale |
| 2023 |
$700–$750 |
Stable, with slight downward pressure due to biosimilar threats. |
| 2024 |
$680–$730 |
Market competition intensifies; manufacturers may implement discounts. |
| 2025 |
$660–$720 |
Biosimilar candidates expected to launch; price adjustments expected. |
| 2026 |
$640–$700 |
Increased biosimilar market share could push prices further downward. |
| 2027 |
$620–$680 |
Greater biosimilar penetration, potential for new indication-based pricing models. |
Price Drivers and Risks
- Biosimilar entry scheduled around 2024-2025 could halve or reduce by approximately 20%-30% the existing WAC.
- Increased competition from newer agents like semaglutide.
- Market dynamics influenced by payer strategies and formulary placements.
- Patent expirations could lead to significant price reductions.
Key Takeaways
- Victoza currently commands a WAC of approximately $700–$750 per pen.
- The global GLP-1 market accounts for about 35% of the $52 billion diabetes drug market.
- Market share remains robust but is threatened by biosimilars and alternative therapies.
- Price projections suggest gradual declines, with possible drops of 10-20% over five years due to biosimilar competition.
- Reimbursement policies and authorization impact actual prices paid by payers and patients.
FAQs
Q1: When are biosimilars for Victoza expected to enter the market?
Biosimilars are projected to launch around 2024-2025, contingent on patent litigation and regulatory approvals.
Q2: How does Victoza compare price-wise with competitors?
Victoza's WAC is roughly comparable to Trulicity but higher than some biosimilars. Semaglutide offers a once-weekly alternative often at a similar or lower cost due to market competition.
Q3: What factors influence Victoza's market share?
Efficacy, dosing frequency, safety profile, reimbursement, and competitive offerings influence its market share.
Q4: Will increased obesity treatment applications impact Victoza’s pricing?
Yes, expanded indications like weight management could increase demand, potentially impacting pricing strategies.
Q5: What is the outlook for patient out-of-pocket costs?
Insurance coverage improvements could lower out-of-pocket costs; otherwise, prices could face downward pressure due to market competition.
References
[1] MarketLine. (2022). Global Diabetes Drugs Market Report.
